Program for Early Recovery and Resilience Building from EVD Outbreak in Liberia
mBio, Vol. 6 Issue 2, March/April 2015
Available evidence demonstrates that direct patient contact and contact with infectious body fluids are the primary modes for Ebola virus transmission, but this is based on a limited number of studies. In this review, the authors address what we know and what ...we do not know about Ebola virus transmission. They also hypothesize that Ebola viruses have the potential to be respiratory pathogens with primary respiratory spread.
more
In response to a call by the United Nations Secretary-General and the Governments of Guinea, Liberia and Sierra Leone, an international team conducted an Ebola Recovery Assessment.The aim was to contribute towards laying the foundation for short-, medium- and long-term recovery while the medical eme...rgency response continues to tackle the epidemic.
This summary report is based on a full report as well as three detailed reports submitted to each of the three governments as contributions to their national recovery planning processes.
more
A quick reference guide for health authorities and health-care workers
Revised 2015
Almost 30 countries vulnerable to a new Ebola-style Epidemic, jeopardising the future of millions of Children. The report ranks the world’s poorest countries on the state of their public health systems, finding that 28 have weaker defences in place than Liberia where, alongside Sierra Leone and Gu...inea, the current Ebola crisis has already claimed 9,000 lives, and provoked an extraordinary international response to help contain it.
more
Summary of research into the consequences of the Ebola outbreak for children and communities in Liberia and Sierra Leone
This study describes the range of impacts that Ebola has had on children and families in Liberia and Sierra Leone, looking beyond the immediate health effects
BMC Medicine (2015) 13:42 DOI 10.1186/s12916-014-0263-6
Recommandations francaises pour la prise enc harge du chikungunya
Médecine e tmaladies infectieuses 45(2015)243–263
WHO published and launched the third part of the Wheelchair Service Training Package (WSTP) series consisting of two sub-packages: the Wheelchair Service Training Package for Managers (WSTPm) and the Wheelchair Service Training Package for Stakeholders (WSTPs). WHO recognises that in order to develo...p an effective and sustainable wheelchair service provision; managers and stakeholders need to be informed about the importance and benefit of a proper wheelchair service provision. The training manuals and introductory folder comes with 8 GB PenDrive, which contains A to Z of the wheelchair provision.
more
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o...f their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all the unwanted effects of medications are mentioned.
more
Update of the Mental Health Gap Action Programme
(mhGAP) Guideline for Mental, Neurological and Substance use Disorders May 2015
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more